3 hours Aquestive Therapeutics (NASDAQ:AQST) Stock Rating Reaffirmed by Leerink Partners MarketBeat
Leerink Partners reissued an “outperform” rating and set a $12.00 target price (up previously from $10.00) on shares of Aquestive Therapeutics in a research note on Monday.